Oct 23, 2024
Oct 23, 2024
chat
CDC ACIP Meeting: COVID-19, Influenza, RSV + Pneumococcal Vaccines | Oct. 23
Agenda (in Eastern Time)
- 8:00am — Welcome and Introductions
- 8:20am — Pneumococcal Vaccines
- 10:30am — Break
- 10:40am — Influenza Vaccines
- 11:25am — Chikungunya Vaccines
- 12:10pm — Break
- 12:40pm — COVID-19 Vaccines
- 3:35pm — Break
- 3:45pm — Public Comment
- 4:05pm — Voting (Pneumococcal, Influenza, COVID-19)
- 4:35pm — RSV Vaccines
- 5:30pm — Recess
CHD.TV offers a wide range of content pertaining to children's health. We regularly stream hearings, meetings and lectures from the World Economic Forum, National Institutes of Health, World Health Organization and other entities to keep you up to date the tactics and ideologies of those who influence public health, though Children's Health Defense may not have any affiliation with these organizations or individuals.
*The opinions expressed by the hosts and guests in this show are not necessarily the views of Children’s Health Defense.
Resources
Pneumococcal Vaccines | Presentation Slides
Economic Analysis and Public Health Impact of PCV | Presentation Slides
Summary of three economic analyses on the use of PCV | Presentation Slides
Summary of Work Group Interpretation of EtR and Policy Options | Presentation Slides
Influenza Work Group—Introduction | Presentation Slides
2023–24 End of Season Influenza Vaccine Effectiveness – United States | Presentation Slides
Highly Pathogenic Avian Influenza A (H5N1) | Presentation Slides
CHIKUNGUNYA VACCINES | Presentation Slides
Update on chikungunya and chikungunya vaccines | Presentation Slides
CHIKV VLP vaccine Bavarian Nordic’s chikungunya vaccine candidate | Presentation Slides
Work Group interpretation of data for virus-like particle chikungunya vaccine | Presentation Slides
ACIP COVID-19 Vaccines Work Group | Presentation Slides
Implementation Considerations for Additional COVID-19 Vaccine Doses | Presentation Slides
Effectiveness of COVID-19 vaccines | Presentation Slides
Economic analysis of an additional dose of the 2024-2025 COVID-19 vaccine | Presentation Slides
Maternal/Pediatric Respiratory Syncytial Virus (RSV) Work Group | Presentation Slides
Clesrovimab (MK-1654): Pediatric Clinical Program | Presentation Slides
Maternal & Pediatric RSV Work Group Interpretations and Next Steps | Presentation Slides